Evolocumab mechanism to reduce LDL cholesterol

No Pathway Network information available for Evolocumab mechanism to reduce LDL cholesterol

#	Name	Source	Genes
1	Evolocumab mechanism to reduce LDL cholesterol	WikiPathways	LDLR PCSK9
2	PCSK9-mediated LDL receptor degradation	WikiPathways	LDLR PCSK9

Ordered by rank within the SuperPath, via the multiplicity of each gene in the constituent pathways

#	Symbol	Description	Category	# Related Pathways
1	LDLR	Low Density Lipoprotein Receptor	Protein Coding	2
2	PCSK9	Proprotein Convertase Subtilisin/Kexin Type 9	Protein Coding	2

according to GeneCards Suite gene sharing

#	Disorder	Type	Genes	Score
1	Homozygous familial hypercholesterolemia	Enrichment	LDLR, PCSK9	6.52
2	Hypercholesterolemia, familial, 1	Enrichment	LDLR, PCSK9	6.07
3	Familial hypercholesterolemia	Enrichment	LDLR, PCSK9	5.94
4	Hypercholesterolemia, familial, 3	Enrichment	PCSK9	3.83
5	Hyperlipoproteinemia, type iii	Enrichment	LDLR	3.53
6	Hypercholesterolemia, familial, 2	Enrichment	LDLR	3.35
7	Intellectual developmental disorder with microcephaly and pontine and cerebellar hypoplasia	Enrichment	LDLR	3.35
8	Hypercholesterolemia, familial, 4	Enrichment	LDLR	3.35
9	Syndromic x-linked intellectual disability najm type	Enrichment	LDLR	3.35
10	Hyperlipidemia, familial combined, 3	Enrichment	LDLR	3.13
11	Cowden syndrome 1	Enrichment	LDLR	3.05
12	Lipid metabolism disorder	Enrichment	LDLR	3.05
13	Coronary heart disease 5	Enrichment	LDLR	2.88

¹ WikiPathways

² PubChem

³ R&D Systems

⁴ Reactome

⁵ GeneGo (Thomson Reuters)

⁶ QIAGEN

⁷ PharmGKB

⁹ Sino Biological

¹⁰ Tocris

¹¹ MalaCards

Pathway Network for Evolocumab mechanism to reduce LDL cholesterol